Genetics of malignant hyperthermia: A brief update

David Beebe, Vikram Puram, Srdjan Gajic, Bharat Thyagarajan, Kumar Belani

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Malignant hyperthermia susceptibility (MHS) and the associated condition malignant hyperthermia (MH) are rare but well-known disorders in the field of anesthesiology. MHS is usually determined by a history of a family member developing a positive episode during general anesthesia and then confirmed by an invasive caffeine halothane contracture test (CHCT). More recently, within the context of MH as a pharmacogenetic disorder, the question of whether or not MHS can be principally genetically determined is of high importance as knowledge of detailed pathogenesis may prevent against its largely invariable lethality if untreated. Thus, in this brief report, genetic terms, as well as updates in the genetics of MHS, will be reviewed in order to better understand both the condition and the current research.

Original languageEnglish (US)
Pages (from-to)552-555
Number of pages4
JournalJournal of Anaesthesiology Clinical Pharmacology
Issue number4
StatePublished - Oct 1 2020

Bibliographical note

Publisher Copyright:
© 2020 Wolters Kluwer Medknow Publications. All rights reserved.


  • Genetic testing
  • MH susceptibility
  • malignant hyperthermia (MH)


Dive into the research topics of 'Genetics of malignant hyperthermia: A brief update'. Together they form a unique fingerprint.

Cite this